Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25628692 | 0.87 | ALDH1A1 (0.37) | NPSR1POLB | |
| SCHEMBL25478800 | 0.86 | USP1 (0.35) | USP1NPSR1POLB | |
| SCHEMBL25613560 | 0.83 | USP1 (0.34) | USP1NPSR1ALOX15CASR | |
| SCHEMBL25628685 | 0.79 | USP1 (0.35) | USP1 | |
| SCHEMBL25628791 | 0.77 | HTR2A (0.40) | — | |
| SCHEMBL24005542 | 0.75 | USP1 (0.37) | USP1NPSR1CASRPOLB | |
| SCHEMBL25613665 | 0.74 | USP1 (0.36) | USP1NPSR1CASRPOLB | |
| SCHEMBL24775488 | 0.74 | CHRNA7 (0.38) | — | |
| SCHEMBL25628656 | 0.74 | L3MBTL1 (0.36) | — | |
| SCHEMBL25628893 | 0.73 | PKM (0.38) | NPSR1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2021223736-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | USP1 2722/4885NPSR1 4848/4885ALOX15 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.